Cargando…
Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies
BACKGROUND: Successful treatments of patients with somatostatin receptor (SSTR)-overexpressing neuroendocrine tumours (NET) comprise somatostatin-analogue lutetium-177-labelled octreotate ((177)Lu-TATE) treatment, also referred to as peptide receptor radionuclide therapy (PRRT), and temozolomide (TM...
Autores principales: | Bison, Sander M., Haeck, Joost C., Bol, K., Koelewijn, S. J., Groen, H. C., Melis, M., Veenland, J. F., Bernsen, M. R., de Jong, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639542/ https://www.ncbi.nlm.nih.gov/pubmed/26553049 http://dx.doi.org/10.1186/s13550-015-0142-y |
Ejemplares similares
-
Peptide receptor radionuclide therapy (PRRT) with [(177)Lu-DOTA(0),Tyr(3)]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model
por: Bison, Sander M, et al.
Publicado: (2014) -
Can DCE-MRI Explain the Heterogeneity in Radiopeptide Uptake Imaged by SPECT in a Pancreatic Neuroendocrine Tumor Model?
por: Bol, Karin, et al.
Publicado: (2013) -
Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments
por: Bison, Sander M., et al.
Publicado: (2014) -
Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements
por: Merola, Elettra, et al.
Publicado: (2023) -
Imaging heterogeneity of peptide delivery and binding in solid tumors using SPECT imaging and MRI
por: Haeck, J. C., et al.
Publicado: (2016)